Northern, WI 4/4/12 (StreetBeat) -- Expanding its footprint in cancer treatment, Access Pharmaceuticals, Inc. (OTCBB: ACCP) said today that Memorial Sloan-Kettering Cancer Center (MSKCC), one of the world's premier cancer centers, has added MuGard to its cancer supportive care pharmacy formulary. Patients undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.Oral mucositis is a significant health issue for all cancer patients with more than 40 percent of all patients citing it as one of the most bothersome side effects of radiotherapy and chemotherapy. Head and neck cancer patients are especially at risk of oral mucositis with incident rates in excess of 90 percent.
"Having a world-renowned institution like Memorial Sloan-Kettering add MuGard to its formulary is a monumental step in our mission to increase MuGard access for cancer patients," said Frank Jacobucci, Vice President Sales and Marketing, Access Pharmaceuticals, Inc. He continued, "Dedicated to the progressive control and cure of cancer, MSKCC is considered one of the best cancer treatment institutions in the world and we are pleased that it has taken action, after their evaluation of MuGard, to treat and potentially eliminate oral mucositis, a debilitating side effect that is often times detrimental to anticancer treatments and lessens the quality of life for cancer patients.
Access Pharma also gave a reminder about a conference call for today which was held at 11 AM EDT. Those who did not attend can listen to a replay of the call starting on April 4, 2012 at 1:00 pm ET, through April 18, 2012 until 11:59 pm ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering account number 383 and conference ID number 377785.
Please contact www.thestreetbeat.com for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail bflautt@gmail.com or call (662) 392-0740 for pricing and scheduling.
StreetBeat Disclaimer
No comments:
Post a Comment